Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma.
allogeneic
cell therapy
dendritic cells
hepatocellular carcinoma
ilixadencel
immunotherapy
sorafenib
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
09
2018
accepted:
07
01
2019
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
6
2
2019
Statut:
epublish
Résumé
Several lines of evidence support immunotherapy in hepatocellular carcinoma (HCC). We have shown that intratumoral injections of the immune primer ilixadencel (pro-inflammatory allogeneic dendritic cells) are safe in renal-cell carcinoma. Here, we assessed ilixadencel as a single agent and combined with sorafenib in advanced HCC. Of 17 HCC patients enrolled, 12 patients received ilixadencel at the dose of 10 × 10
Identifiants
pubmed: 30719425
doi: 10.3389/fonc.2019.00019
pmc: PMC6348253
doi:
Banques de données
ClinicalTrials.gov
['NCT01974661']
Types de publication
Case Reports
Langues
eng
Pagination
19Références
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Immunity. 2001 Apr;14(4):357-68
pubmed: 11336681
J Clin Oncol. 2005 Feb 10;23(5):999-1010
pubmed: 15598979
Scand J Immunol. 2005 Sep;62(3):234-42
pubmed: 16179010
Blood. 2008 Jun 15;111(12):5610-20
pubmed: 18310500
Cancer Res. 2008 Jul 15;68(14):5965-71
pubmed: 18632652
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Int J Cancer. 2009 Jul 15;125(2):367-73
pubmed: 19378341
Cancer. 2009 Dec 15;115(24):5651-61
pubmed: 19834957
J Clin Oncol. 2010 Sep 1;28(25):3994-4005
pubmed: 20679622
Lab Invest. 2011 Apr;91(4):598-608
pubmed: 21321535
PLoS One. 2011 Apr 20;6(4):e18801
pubmed: 21533099
Clin Liver Dis. 2011 May;15(2):223-43, vii-x
pubmed: 21689610
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Clin Cancer Res. 2013 Apr 1;19(7):1858-72
pubmed: 23444227
Nefrologia. 2014;34(1):115-9
pubmed: 24463868
Clin Cancer Res. 2014 Apr 15;20(8):2072-9
pubmed: 24589894
JAMA. 2014 Jul 2;312(1):57-67
pubmed: 25058218
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 2015 Jan 10;33(2):172-9
pubmed: 25488963
J Clin Oncol. 2015 Feb 20;33(6):559-66
pubmed: 25547503
Lancet Oncol. 2015 Jul;16(7):859-70
pubmed: 26095784
World J Gastroenterol. 2015 Sep 28;21(36):10314-26
pubmed: 26420958
JCI Insight. 2016 Jul 21;1(11):null
pubmed: 27540594
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Cell. 2017 Jun 1;169(6):1130-1141.e11
pubmed: 28552348
Am Soc Clin Oncol Educ Book. 2017;37:311-317
pubmed: 28561676
J Immunother Cancer. 2017 Jun 20;5:52
pubmed: 28642820
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Oncoimmunology. 2017 Nov 27;7(3):e1395126
pubmed: 29399392
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Pharm Res. 2018 Jun 14;35(8):156
pubmed: 29904904
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759